The table below shows BioXcel Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$11.81M
-$12.04M
-$17.71M
-$52.35M
-$32.41M
-$19.64M
Capital expenditure
$0.00
$0.00
-
-
$120.00K
$316.00K
Investing cash flow
$0.00
$0.00
-
-
-$120.00K
-$316.00K
Dividends paid
-
-
-
-
BTAI operating cash flow (10-K history)
BioXcel Therapeutics, Inc. reported operating cash flow of -$57.62M for fiscal year 2025. That is up 20.0% from -$72.03M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow declined from -$2.20M (FY 2017) to -$57.62M. Figures come from the company's audited annual reports as filed with the SEC.